|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |  |   |   |   |   |   |
|   |  |  |  |  |  |  |  |   |
|   | **17 patients with consent****15 patients included****14 patients evaluable for main analysis** **11 patients with PCI <17 for sensitivity and specificity analysis**

|  |
| --- |
|  |

 |  |  |  |  |  |  |   |
|   |  |  |  | **Excluded from overall analysis (2)****- Unexpected extent of disease (1)****- Absence of tumoral disease (1)** |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  | **Non evaluable (1)****- Only ICG IV 24h before surgery** |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  | **Further excluded from sensitivity and specificity analysis****- PCI > 17 (3)** |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |  |  |  |  |  |  |  |   |
|   |   |   |   |   |   |   |   |   |

**Supplemental Digital Content Figure 1 : Included patients**